多巴胺和抗胆固醇治疗对帕金森病手生理复杂性的影响:一项随机交叉研究
Yusha Cui1,2, Dongning Su1,2, Junjiao Zhang1,2
1Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
CNS neuroscience & therapeutics
|October 31, 2023
概括
列沃多巴增加了震的复杂性,而本泽在帕金森震 (PT) 患者中降低了它. 震复杂性变化与临床评级相关,表明其作为PT药物效应生物标志物的潜力.
科学领域:
- 神经科学是一个神经科学.
- 生物医学工程 生物医学工程
- 临床药理学 临床药理学
背景情况:
- 帕金森发 (PT) 的特征是由多种神经生理因素调节的复杂波动.
- 了解震复杂性的动态对于评估治疗疗效至关重要.
研究的目的:
- 为了研究多巴和泽对帕金森的震复杂性的影响.
- 探索震复杂性,认知任务和临床评级之间的关系.
主要方法:
- 66名参与者在随机交叉设计中接受了莱沃多巴或泽.
- 在各种条件下 (休息,姿势,加重,有/没有认知任务) 使用表面电磁共振和加速度计记录震动波动.
- 采用多尺度分析来量化震的复杂性.
主要成果:
- 认知任务在休息和姿势条件下降低了的复杂性.
- 列沃多巴增加了震复杂性,而本泽与基线相比降低了它.
- 震复杂性的变化和药物诱导的变化与临床评估有显著的相关性.
结论:
- 震的复杂性是帕金森震的敏感标志物.
- 量化的复杂性可以帮助描述药物对PT病理生理学的影响.
- 这种方法可能有助于优化帕金森的治疗策略.
相关概念视频
Parkinson's Disease: Treatment
281
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
281
Parkinson's Disease: Overview
567
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
567
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
698
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
698
Cholinergic Antagonists: Pharmacological Actions
1.1K
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
1.1K
Direct-Acting Cholinergic Agonists: Pharmacological Actions
1.4K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
1.4K
Cholinergic Antagonists: Therapeutic Uses
758
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
758


